PL3230318T3 - Kombinacje inhibitora immunologicznego punktu kontrolnego - Google Patents

Kombinacje inhibitora immunologicznego punktu kontrolnego

Info

Publication number
PL3230318T3
PL3230318T3 PL15793746T PL15793746T PL3230318T3 PL 3230318 T3 PL3230318 T3 PL 3230318T3 PL 15793746 T PL15793746 T PL 15793746T PL 15793746 T PL15793746 T PL 15793746T PL 3230318 T3 PL3230318 T3 PL 3230318T3
Authority
PL
Poland
Prior art keywords
immune checkpoint
checkpoint inhibitor
inhibitor combinations
combinations
immune
Prior art date
Application number
PL15793746T
Other languages
English (en)
Inventor
Liv Marie EIKE
Ketil CAMILIO
Baldur SVEINBJØRNSSON
Laurence Zitvogel
Takahiro Yamazaki
Øystein REKDAL
John Sigurd Mjøen SVENDSEN
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506127.8A external-priority patent/GB201506127D0/en
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of PL3230318T3 publication Critical patent/PL3230318T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15793746T 2014-12-11 2015-11-04 Kombinacje inhibitora immunologicznego punktu kontrolnego PL3230318T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201422084 2014-12-11
GBGB1506127.8A GB201506127D0 (en) 2015-04-10 2015-04-10 Immune checkpoint inhibitor combinations
JP2015118495A JP6767096B2 (ja) 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ
EP15793746.7A EP3230318B1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
PCT/EP2015/075722 WO2016091487A1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations

Publications (1)

Publication Number Publication Date
PL3230318T3 true PL3230318T3 (pl) 2021-03-08

Family

ID=56384106

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15793746T PL3230318T3 (pl) 2014-12-11 2015-11-04 Kombinacje inhibitora immunologicznego punktu kontrolnego

Country Status (11)

Country Link
US (3) US11083774B2 (pl)
EP (1) EP3230318B1 (pl)
JP (1) JP6767096B2 (pl)
AU (3) AU2015359881B2 (pl)
DK (1) DK3230318T3 (pl)
ES (1) ES2819282T3 (pl)
HU (1) HUE051268T2 (pl)
LT (1) LT3230318T (pl)
PL (1) PL3230318T3 (pl)
PT (1) PT3230318T (pl)
WO (1) WO2016091487A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
JP6810877B2 (ja) * 2016-12-26 2021-01-13 国立大学法人神戸大学 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療
WO2018188761A1 (en) * 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
US11759485B2 (en) 2018-06-14 2023-09-19 Meiji Co., Ltd. Composition for enhancing immune checkpoint blockade therapy
SG11202112875UA (en) 2019-06-20 2021-12-30 Chemocentryx Inc Compounds for treatment of pd-l1 diseases
CN110317245B (zh) * 2019-08-02 2021-04-09 郑州大学 Lag-3蛋白亲和环肽及其应用
MX2022004450A (es) 2019-10-16 2022-05-03 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
US20230037966A1 (en) * 2020-01-07 2023-02-09 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
WO2024133588A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan
WO2024133580A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide
CN117402828A (zh) * 2023-04-13 2024-01-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种人肺癌脑转移瘤细胞系及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CN1309569A (zh) 1998-05-04 2001-08-22 托马斯杰斐逊大学 含有肿瘤细胞和提取物的组合物及其使用方法
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
FI2206517T3 (fi) * 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP3375791A1 (en) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US9410206B2 (en) * 2011-11-30 2016-08-09 John Wayne Cancer Institute Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
EP3060581A4 (en) * 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015127407A1 (en) * 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2968406A1 (en) * 2014-12-09 2016-06-16 Mark D. Ayers System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ

Also Published As

Publication number Publication date
EP3230318B1 (en) 2020-06-24
AU2015359881B2 (en) 2019-02-07
AU2019203199A1 (en) 2019-05-30
AU2019203199B2 (en) 2021-04-01
US20240293506A1 (en) 2024-09-05
DK3230318T3 (da) 2020-08-31
US20230201305A9 (en) 2023-06-29
ES2819282T3 (es) 2021-04-15
AU2021204356B2 (en) 2024-10-03
US20180264079A1 (en) 2018-09-20
AU2021204356A1 (en) 2021-07-22
PT3230318T (pt) 2020-09-21
EP3230318A1 (en) 2017-10-18
US20210401933A1 (en) 2021-12-30
WO2016091487A1 (en) 2016-06-16
JP2016128399A (ja) 2016-07-14
LT3230318T (lt) 2020-10-12
HUE051268T2 (hu) 2021-03-01
US11083774B2 (en) 2021-08-10
JP6767096B2 (ja) 2020-10-14
AU2015359881A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
SG11201701322WA (en) Special effects techniques
HK1243415A1 (zh) 溴結構域抑制劑
AU361515S (en) Dishrack
IL239830B (en) Case
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
AU359704S (en) Case
AU362944S (en) Lapboard
IL238537A0 (en) Multi-purpose frisbee-umbrella
HUE051268T2 (hu) Immunellenõrzõpont-gátló kombinációk
GB2526680B (en) Runway arrangement
GB201419650D0 (en) Modified heterocyclase
GB201401005D0 (en) Inhibitor
GB2531245B (en) Ramp
GB2523854B (en) Circuitry
GB201416600D0 (en) Glycobiological surfaces
GB201506127D0 (en) Immune checkpoint inhibitor combinations
AU5286P (en) FLOMANWHW Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi
GB201421232D0 (en) Retro-reflector
GB201418154D0 (en) Inhibitors
GB201420353D0 (en) Mechanical fastener
AU2014265V (en) FlatdampGL Westringia dampieri